共 50 条
Risk, Incidence, and Mortality of Breast Cancer in Primary Sjogren's Syndrome: A Systematic Review and Meta-Analysis
被引:8
|作者:
Deng, Jian
[1
,2
]
Liu, Mengsi
[3
]
Xiao, Ruoyi
[3
]
Wang, Jin
[3
]
Liao, Xibei
[3
]
Ye, Zhen
[3
]
Sun, Zhen
[3
]
机构:
[1] Univ South China, Affiliated Hosp 2, Hengyang Med Sch, Dept Thyroid Breast Surg, Hengyang, Peoples R China
[2] Univ South China, Affiliated Hosp 2, Ctr Breast Canc Prevent & Treatment, Hengyang Med Sch, Hengyang, Peoples R China
[3] Univ South China, Hengyang Med Sch, Dept Clin Med, Hengyang, Peoples R China
来源:
关键词:
primary Sjogren's syndrome (pSS);
breast cancer;
risk factor;
protective factor;
mortality;
incidence;
meta-analysis;
MALIGNANCY RISK;
COHORT;
ASSOCIATION;
DISEASES;
LYMPHOMA;
D O I:
10.3389/fimmu.2022.904682
中图分类号:
R392 [医学免疫学];
Q939.91 [免疫学];
学科分类号:
100102 ;
摘要:
Background: Primary Sjogren's syndrome (pSS) and breast cancer are a highly prevalent autoimmune disease and malignancy, respectively, both occurring predominantly in females. Whether there is a link between these two diseases is uncertain. We conducted a systematic review and meta-analysis to investigate the risk, incidence, and mortality of breast cancer in patients with pSS. Methods: We systematically searched Embase, PubMed, and Web of Science on January 31, 2022 to identify the study that assessed risk, incidence, or mortality of breast cancer in pSS. The fixed or random-effects models were applied to pool the effect estimates based on heterogeneity measured by Cochran's Q-test and Higgins' I-2. Results: Ten studies involving 725,805 participants and 64,836 pSS patients were included in our analysis. The pooled result showed that, overall, pSS was not associated with the risk (SIR=0.92, 95%CI: 0.66-1.29, P=0.646) and mortality (HR = 0.78, 95%CI: 0.26-2.34, P = 0.664) of breast cancer; however, when stratified by geographic region, we found that patients with pSS in Asian countries (SIR=1.32, 95%CI: 1.10-1.58, P=0.003) and Argentina (SIR=3.76, 95%CI: 1.04-9.45, P=0.019) had an elevated risk of breast cancer, while pSS in Europe was associated with a reduced risk (SIR=0.61, 95%CI: 0.51-0.73, P < 0.001). The pooled result from 28,635 female pSS patients indicated that the incidence of breast cancer was 2.15 (95% CI: 1.33-3.50) per 1000 person/years. Conclusion: This study suggests that there may be geographical differences in the association between pSS and breast cancer risk; patients with pSS in European countries are associated with a lower risk of breast cancer, while Asia and Argentina are the opposite. Future research is needed to further characterize the effect of pSS on breast cancer risk and the pathophysiological mechanisms underlying this association to unravel the complex relationship between the two.
引用
收藏
页数:8
相关论文